Intra Cellular Therapies | Spese Di Vendita E Di Amministrazione



Selling And Administration Expenses Cambiamento Data
Acadia Pharmaceuticals USD 130.08M 3.21M 2024-12
ALKERMES USD 146.99M 3.39M 2024-12
Biogen USD 677.3M 99.6M 2024-12
Bristol-Myers Squibb USD 2.1B 129M 2024-12
Cytokinetics USD 62.34M 5.69M 2024-12
Gilead Sciences USD 1.86B 451M 2024-12
Halozyme Therapeutics USD 42.25M 1.01M 2024-12
Intra Cellular Therapies USD 137.73M 5.63M 2024-12
J&J USD 6.45B 975M 2024-12
Neurocrine Biosciences USD 287.8M 53.5M 2024-12
Novartis USD 3.5B 368M 2024-12
Prothena USD 16.85M 88K 2024-12
RedHill Biopharma USD 4.48M 1.52M 2024-03
Supernus Pharmaceuticals USD 79.41M 9.66M 2024-12
United Therapeutics USD 162.5M 8.4M 2024-12



Intra Cellular Therapies Spese Di Vendita E Di Amministrazione - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - Mar 2025.